Intraperitoneal (IP) chemotherapy is a reasonable treatment approach for ovarian cancer because it can directly expose the surface tissues to which the cancer has disseminated to an extremely high concentration of the chemotherapy drug.
Keiichi Fujiwara, MD, PhD
Advertisement
Articles by Keiichi Fujiwara, MD, PhD
The article by Dr. Echarri Gonzalez and her colleagues regarding intraperitoneal (IP) chemotherapy for women with epithelial ovarian cancer provides a comprehensive yet practical review of the critical questions surrounding the use of IP chemotherapy.
Advertisement
Latest Updated Articles
- Use of IP Chemotherapy in Ovarian Cancer: The Critical Questions
Published: February 21st 2011 | Updated:
POINT: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer?Published: February 15th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
3
FDA Approves Revumenib in R/R NPM1-Mutant AML
4
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
5
